Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Pharmaceutical - Page 5

Pharmaceutical

COVID-19 heroes & Remembrance
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | FDA | Life Science History | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 heroes & Remembrance

Our Heroes and Remembrance illustration has Maurice Ralph Hilleman and John Enders, pioneering developers of common vaccines, and…

Read More COVID-19 heroes & RemembranceContinue

Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in Japan
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in Japan

On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanメs Ministry of Health, Labor and Welfare had…

Read More Merck and Ridgeback’s molnupiravir, an investigational oral antiviral COVID-19 treatment, received special approval for emergency in JapanContinue

Pfizer and BioNTech submit updated longer-term follow-up data of COMIRNATY in adolescents to EMA
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech submit updated longer-term follow-up data of COMIRNATY in adolescents to EMA

On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesメ…

Read More Pfizer and BioNTech submit updated longer-term follow-up data of COMIRNATY in adolescents to EMAContinue

Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19
Biotechnology | COVID-19 | FDA | Medicine | Pharmaceutical | Therapeutics

Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19

On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…

Read More Merck and Ridgeback’s molnupiravir received U.S. FDA EUA for treatment of high-risk adults with COVID-19Continue

Pfizer and BioNTech provided EU more than 200 million additional doses of COMIRNATY for vaccine supply
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech provided EU more than 200 million additional doses of COMIRNATY for vaccine supply

On Dec. 20, 2021, Pfizer and BioNTech announced an agreement had been reached with the European Commission (EC)…

Read More Pfizer and BioNTech provided EU more than 200 million additional doses of COMIRNATY for vaccine supplyContinue

Pfizer and BioNTech provided update on Omicron variant
COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech provided update on Omicron variant

On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…

Read More Pfizer and BioNTech provided update on Omicron variantContinue

Diverse genome sequences provided a powerful tool for studying risk of heart disease
Biotechnology | Diagnostics | Disease | Genomics | Pharmaceutical | Therapeutics

Diverse genome sequences provided a powerful tool for studying risk of heart disease

On Dec. 8, 2021, in a large-scale study of people from diverse ancestries, researchers narrowed down the number…

Read More Diverse genome sequences provided a powerful tool for studying risk of heart diseaseContinue

COVID-19 roller coaster
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Life Science History | Medicine | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 roller coaster

The COVID-19 Roller Coaster is a wild ride, strap yourself in and hold on… Cast of Characters: Senator…

Read More COVID-19 roller coasterContinue

Pfizer’s COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Pfizer’s COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis

On Nov. 5, 2021, Pfizer announced it was investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization…

Read More Pfizer’s COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysisContinue

Ronapreve approved for additional indication as preventive treatment of symptomatic COVID-19 in Japan
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Ronapreve approved for additional indication as preventive treatment of symptomatic COVID-19 in Japan

On Nov. 5, 2021, Chugai Pharmaceutical, announced that it had obtained approval from the Ministry of Health, Labour…

Read More Ronapreve approved for additional indication as preventive treatment of symptomatic COVID-19 in JapanContinue

Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccine
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccine

On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses…

Read More Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccineContinue

Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine

On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…

Read More Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccineContinue

Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY

On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products…

Read More Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATYContinue

Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY

On Oct. 15, 2021, Pfizer and BioNTech announced they had submitted data supporting the vaccination of children 5…

Read More Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATYContinue

Resilience collaborated with Children’s Hospital of Philadelphia to develop next-gen biomanufacturing technologies
COVID-19 | Disease | HIV | Measles | Medicine | Pharmaceutical | Therapeutics | Vaccine

Resilience collaborated with Children’s Hospital of Philadelphia to develop next-gen biomanufacturing technologies

On Oct. 12, 2021, National Resilience announced a strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to implement…

Read More Resilience collaborated with Children’s Hospital of Philadelphia to develop next-gen biomanufacturing technologiesContinue

Pfizer and BioNTech received CHMP positive opinion for COVID-19 vaccine booster in the European Union
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech received CHMP positive opinion for COVID-19 vaccine booster in the European Union

On Oct. 4, 2021, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…

Read More Pfizer and BioNTech received CHMP positive opinion for COVID-19 vaccine booster in the European UnionContinue

Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 study
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 study

On Oct. 1, 2021, Merck and Ridgeback Biotherapeutics announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine,…

Read More Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 studyContinue

COVID-19 vaccinated vs. non-vaccinated
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medical Device | Neurology | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 vaccinated vs. non-vaccinated

This cartoon illustrates the various issues facing individuals across the U.S. who are vaccinated against COVID-19 verus those…

Read More COVID-19 vaccinated vs. non-vaccinatedContinue

Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine

On Sept. 29, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…

Read More Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccineContinue

Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19

On Sept. 29, 2021, Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreveル (casirivimab and…

Read More Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19Continue

Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Pharmaceutical | Vaccine

Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate

On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given…

Read More Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidateContinue

Regeneron announced U.S. Government agreement to purchase additional REGEN-COV antibody cocktail
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Regeneron announced U.S. Government agreement to purchase additional REGEN-COV antibody cocktail

On Sept. 14, 2021, Regeneron announced an agreement with the U.S. Department of Health and Human Services and…

Read More Regeneron announced U.S. Government agreement to purchase additional REGEN-COV antibody cocktailContinue

Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATY
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATY

On Sept. 6, 2021, Pfizer and BioNTech announced that they had submitted a variation to the European Medicines…

Read More Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATYContinue

INOVIO received authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate, INO-4800 in Brazil
Biotechnology | COVID-19 | Pharmaceutical | Vaccine

INOVIO received authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate, INO-4800 in Brazil

On Aug. 26, 2021, Inovio Pharma announced that it had received regulatory authorization from Brazil’s ANVISA (Agencia Nacional…

Read More INOVIO received authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate, INO-4800 in BrazilContinue

Pfizer and BioNTech initiated rolling submission of SBLA to U.S. FDA for booster dose of COMIRNATY in individuals 16 and Older
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Pfizer and BioNTech initiated rolling submission of SBLA to U.S. FDA for booster dose of COMIRNATY in individuals 16 and Older

On Aug. 25, 2021, Pfizer and BioNTech announced the initiation of a supplemental Biologics License Application (sBLA) to…

Read More Pfizer and BioNTech initiated rolling submission of SBLA to U.S. FDA for booster dose of COMIRNATY in individuals 16 and OlderContinue

Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full U.S. FDA approval for individuals 16 years and older
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics

Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full U.S. FDA approval for individuals 16 years and older

On Aug. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) approved the…

Read More Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full U.S. FDA approval for individuals 16 years and olderContinue

Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variants
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variants

On Jul. 29, 2021, Cocrystal Pharma announced that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed…

Read More Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variantsContinue

COVID-19 vacation Destinations
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine

COVID-19 vacation Destinations

Planning a Summer vacation? Where to go? How about going to one of those large events with tens…

Read More COVID-19 vacation DestinationsContinue

Merck Announces FDA approval of VAXNEUVANCE  for prevention of invasive pneumococcal disease
Biotechnology | FDA | Medicine | Pharmaceutical | Therapeutics

Merck Announces FDA approval of VAXNEUVANCE for prevention of invasive pneumococcal disease

On Jul. 16, 2021, Merck announced the U.S. Food and Drug Administration (FDA) had approved VAXNEUVANCE (Pneumococcal 15-valent…

Read More Merck Announces FDA approval of VAXNEUVANCE for prevention of invasive pneumococcal diseaseContinue

Vibativ effectively helped treat secondary bacterial infections in COVID-19 patients
Biotechnology | COVID-19 | Pharmaceutical

Vibativ effectively helped treat secondary bacterial infections in COVID-19 patients

On Jun. 21, 2021, Cumberland Pharma released a series of case reports describing the effectiveness of Vibativ (telavancin)…

Read More Vibativ effectively helped treat secondary bacterial infections in COVID-19 patientsContinue

Page navigation

Previous PagePrevious 1 … 3 4 5 6 7 … 14 Next PageNext
  • Categories
  • Timeline
  • Aesthetics
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cardiology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemistry
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Quantum
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Banner Advertising

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search